Blood Transfusion/*mortality Combined Modality Therapy Cystectomy/*mortality Humans *Perioperative Care Prognosis Survival Rate Urinary Bladder Neoplasms/pathology/*therapy Bladder cancer Blood transfusion Cystectomy Meta-analysis Oncology Systematic review

Humans *Urinary Bladder Neoplasms/surgery/pathology Lasers Urethra/surgery Treatment Outcome Length of Stay 2-micron laser bladder cancer meta-analysis randomized controlled trials trans-urethral resection of bladder tumor

Aged Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Carcinoma Transitional Cell/*drug therapy/*pathology Female Humans Immune Checkpoint Inhibitors/*therapeutic use Liver Neoplasms/secondary Male Middle Aged Survival Analysis Urinary Bladder Neoplasms/*drug therapy/*pathology bladder cancer immune checkpoint inhibitors immunotherapy meta-analysis urothelial carcinoma

Case-Control Studies Female Humans Male *Menarche Odds Ratio Risk Factors *Urinary Bladder Neoplasms/epidemiology/etiology Bladder cancer Menarche Meta-analysis

Female Humans Male Research Design/*standards Urinary Bladder Neoplasms/*diagnosis/*diagnostic imaging Bladder cancer Magnetic resonance imaging Meta-analysis Vesical Imaging Reporting and Data System

Administration Intravesical Combined Modality Therapy Cystectomy/*methods Humans Neoplasm Recurrence Local/*epidemiology Network Meta-Analysis Randomized Controlled Trials as Topic Urethra Urinary Bladder Neoplasms/*diagnostic imaging/drug therapy/epidemiology/*surgery #BladderCancer #blcsm #uroonc blue-light cystoscopy hexaminolevulinic acid narrow band imaging non-muscle-invasive urothelial carcinoma photodynamic diagnosis single immediate intravesical chemotherapy

新辅助化疗 肌层浸润性膀胱癌 疗效 安全性 Meta分析

Cohort Studies Humans *Hypertension *Metabolic Syndrome/epidemiology Obesity Risk Factors *Urinary Bladder Neoplasms/epidemiology Meta analysis Metabolic syndrome Metabolic syndrome components Urinary bladder neoplasm this study.

Biomarkers Tumor *Carcinoma Transitional Cell/diagnosis Female Humans Male Nuclear Proteins Sensitivity and Specificity *Urinary Bladder Neoplasms/diagnosis/pathology bladder tumor diagnosis meta analysis nuclear matrix protein urine cytology

Cisplatin/adverse effects Humans *Immunotherapy/adverse effects/methods *Muscles/pathology *Neoadjuvant Therapy/adverse effects Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/pathology/therapy chemoimmunotherapy immunotherapy meta-analysis muscle-invasive bladder cancer (MIBC) neoadjuvant commercial or financial relationships that could be construed as a potential conflict of interest.

膀胱肿瘤 磁共振成像 膀胱影像报告和数据系统 肌层浸润 Meta分析

Humans *Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/pathology Infusions Intra-Arterial Chemotherapy Adjuvant Adverse Reactions bladder cancer intra-arterial chemotherapy meta-analysis prognosis

Humans Magnetic Resonance Imaging *Multiparametric Magnetic Resonance Imaging Muscles Prospective Studies Urinary Bladder *Urinary Bladder Neoplasms/diagnostic imaging Bladder cancer Meta-analysis Muscle invasion Vesical imaging-reporting and data system

Female Gene Expression Profiling Gene Regulatory Networks Humans Male Muscles Neoplasm Invasiveness Prognosis *Urinary Bladder Neoplasms/genetics/metabolism rab GTP-Binding Proteins/genetics/metabolism Bladder cancer Gene expression Muscle-invasive bladder cancer Urothelial cancer

Area Under Curve *Carcinoma Transitional Cell Humans In Situ Hybridization Fluorescence ROC Curve Sensitivity and Specificity *Urinary Bladder Neoplasms/pathology Biomarker Cytology Diagnostic Fluorescent in situ hybridization (FISH) Meta-analysis Upper urinary tract urothelial carcinoma (UTUC)

Antibodies Monoclonal Humanized/*therapeutic use *Carcinoma Transitional Cell/drug therapy Humans Prognosis Retrospective Studies *Urinary Bladder Neoplasms/drug therapy Metastatic urothelial carcinoma Pembrolizumab Prognostic factor Janssen and Pfizer. Takahiro Kimura is a paid consultant/advisor of Astellas Bayer Janssen and Sanofi. Shahrokh F. Shariat is a paid as follows: Honoraria: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Consulting or Advisory Role: Astellas AstraZeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen. Speakers Bureau: Astellas Astra Zeneca Bayer BMS Cepheid Ferring Ipsen Janssen Lilly MSD Olympus Pfizer Pierre Fabre Richard Wolf Roche Sanochemia Sanofi Takeda Urogen Movember Foundation. The other authors declare no conflicts of interest associated with this manuscript.

铥激光 经尿道等离子电切 非肌层浸润性膀胱癌 Meta分析

Adjuvants Immunologic Administration Intravesical BCG Vaccine/therapeutic use Bayes Theorem *Covid-19 Duration of Therapy Humans *Mycobacterium bovis Neoplasm Invasiveness Neoplasm Recurrence Local/drug therapy Network Meta-Analysis Pandemics *Urinary Bladder Neoplasms/drug therapy *Urology

Artificial Intelligence Humans Muscles/pathology ROC Curve Sensitivity and Specificity *Urinary Bladder Neoplasms/diagnostic imaging/pathology Bladder cancer Meta-analysis Muscle invasive Radiomics Staging Systematic review

闭孔神经阻滞 经尿道膀胱肿瘤切除术 椎管内麻醉 腹股沟入路 耻骨入路 Meta分析 随机对照试验